Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy
- Resource Type
- Correspondence
- Source
- In
Blood Advances 11 October 2022 6(19):5546-5549 - Subject
Myeloid Neoplasia - Language
- ISSN
- 2473-9529